Antibodies are highly specific for their target molecules, but their poor brain penetrance has restricted their use as PET ligands for imaging of targets within the CNS. The aim of this study was to develop an antibody-based radioligand, using the Tribody TM format, for PET imaging of soluble amyloid-beta (Aβ) protofibrils, which are suggested to cause neurodegeneration in Alzheimer's disease. Antibodies, even when expressed in smaller engineered formats, are large molecules that do not enter the brain in sufficient amounts for imaging purposes. Hence, their transport across the blood-brain barrier (BBB) needs to be facilitated, for example through interaction with the transferrin receptor (TfR). Thus, a Fab fragment of the TfR antibody 8D3 was fused with two single chain variable fragments (scFv) of the Aβ protofibril selective antibody mAb158. Five Tribody TM proteins (A1-A5) were generated with different linkers between the Fab-8D3 and scFv-158. All proteins bound to TfR and Aβ protofibrils in vitro. Three of the proteins (A1-A3) were radiolabeled with iodine-125 and studied ex vivo in wild-type (wt) and transgenic mice overexpressing human Aβ. The systemic pharmacokinetics were similar with half-lives in blood of around 9 h for all three ligands. Brain concentrations at 2 h were around 1% of the injected dose per gram brain tissue, which is similar to what is observed for small molecular radioligands and at least 10-fold higher than antibodies in general. At 72 h, transgenic mice showed higher concentrations of radioactivity in the brain than wt mice (12, 15-and 16-fold for A1, A2 and A3 respectively), except in the cerebellum, an area largely devoid of Aβ pathology. A3 was then labelled with iodine-124 for in vivo positron emission tomography (PET) imaging. Brain concentrations were quantified in six different regions showing a clear distinction both quantitatively and visually between wt and transgenic mice and a good correlation with Aβ pathology. We have thus produced a recombinant, bispecific protein, actively transported into the brain, for PET imaging within the CNS. In a longer perspective, this technique may enable imaging of other proteins involved in neurodegenerative diseases for which imaging agents are completely lacking today.
Introduction
To date, radioligands utilized for PET imaging of CNS proteins are generally based on small molecular weight ( < 500 D) pharmaceuticallike compounds. During recent years, radioligands based on antibodies or antibody fragments have been introduced for imaging of peripheral targets, mainly in the field of oncology (van Dongen et al., 2012) . Compared to many small molecular drugs, antibodies are highly specific for their antigen and are therefore attractive as radioligands as they will give rise to a high specific-to-nonspecific signal. However, the use of antibody based radioligands for imaging of targets in the brain is complicated as free diffusion of small molecules to the brain is restricted by the tight endothelial junctions constituting the bloodbrain barrier (BBB). In general less than 0.1% of the injected antibody dose will enter the brain parenchyma (Bard et al., 2000; Poduslo et al., 1994) . Another limitation is their long half-life in blood, which will contribute to the non-specific signal originating from the vascular volume of the brain. The long half-life of antibodies is primarily attributed to the Fc domain, which can be cleaved off to generate fragments with a faster systemic clearance (Fig. 1A) , making them an attractive option for imaging purposes. However, the limited BBB penetrance remains, and hence, the passage across the BBB must be facilitated by other means.
The transferrin receptor (TfR) is expressed at the BBB and regulates the transport of iron into the brain through its natural ligand transferrin. Previous studies have shown that TfR can be successfully used for receptor mediated transcytosis of therapeutic antibodies (Niewoehner et al., 2014; Yu et al., 2011 Yu et al., , 2014 . We recently showed that TfR could also be used to enhance the brain distribution of a radiolabeled antibody fragment for PET imaging (Sehlin et al., 2016) . By chemically conjugating the TfR antibody 8D3 (Kissel et al., 1998 ) to a F(ab') 2 fragment of the monoclonal antibody mAb158 (Englund et al., 2007) , we selectively visualized amyloid-β (Aβ) protofibrils, which are neurotoxic protein aggregates involved in the neuropathology of Alzheimer's disease (AD) (Sehlin et al., 2016) . However, chemical conjugation as used in the previous study, resulted in a somewhat heterogeneous mixture of molecules containing the two moieties (8D3 and mAb158) conjugated to each other at different sites. Therefore, the obtained bispecific fusion protein was not suitable for clinical applications. In addition, the incorporation of the full length 8D3 potentially resulted in bivalent binding to TfR. Previous studies have indicated that monovalent and/or low affinity binding to TfR is beneficial for efficient delivery of antibodies to the brain (Niewoehner et al., 2014; Yu et al., 2011) .
The aim of the present study was to recombinantly express bispecific ligands, in the format of a Tribody TM (Mertens, 2011; Schoonjans et al., 2000) displaying monovalent TfR binding. Tribodies TM were generated via the heterodimerization of a Fab fragment of 8D3 to form a scaffold, upon which two scFv fragments from mAb158 were incorporated to obtain a high avidity binding to Aβ protofibrils (Fig. 1B) , resulting in efficient transcytosis across the BBB and selective binding to Aβ protofibrils in the brain (Fig. 1C ). PET imaging with the radiolabeled bispecific protein was subsequently used to visualize Aβ in areas known to accumulate misfolded Aβ in relation to brain regions unaffected by Aβ pathology. The PET images were also analyzed with respect to their ability to differentiate between transgenic mice, over-expressing human Aβ, and wild-type (wt) mice.
Materials and methods

Generation of five Tribody TM proteins
The Tribody TM is a trademark of Biotecnol Ltd, the company that owns the technology. Biotecnol Ltd manufactured and supplied the bispecific proteins used in the present study. The Tribodies TM combined a Fab fragment of the TfR antibody 8D3 (Boado et al., 2009 ) with two scFvs of the Aβ protofibril selective mAb158 (Englund et al., 2007) . The sequence of the variable domains of the mAb158 heavy (V H ) and light (V L ) chains were thus connected to form a scFv, which was attached with a peptide linker to the C-termini of the 8D3 light chain and N-terminal half of the heavy chain, respectively. The two chains then naturally dimerized to form an 8D3 Fab fragment with two scFv-158 attached to it. The length of the linkers between Fab-8D3 and scFv-158 was varied as displayed in Table 1 
In vitro binding to Aβ and TfR
Binding of the five bispecific proteins to Aβ protofibrils, defined as soluble Aβ aggregates larger than about 100 kD, eluting in the void volume on a Size Exclusion Superdex 75 column, was assessed in comparison to Aβ monomers and fibrils in solution (Englund et al., 2007) with an inhibition ELISA (Sehlin et al., 2016) . 96-well plates were coated with 45 ng/well of Aβ protofibrils for 2 h at +4°C and then with 1% BSA in PBS for 1 h to lower the non-specific binding. Serially diluted Aβ monomers, protofibrils or fibrils were preincubated 1 h with a fixed concentration of biotinylated protein (A1 -2 nM; A2 -1 nM; A3 -1 nM; A4 -2 nM; A5 -3 nM) in a non-binding plate. The Aβ-Tribody TM solution was then transferred to the Aβ coated plates and incubated for 15 min, followed by detection with streptavidin-conjugated horseradish peroxidase (SA-HRP) (Mabtech AB, Nacka strand, Sweden) and K blue aqueous TMB substrate (Neogen Corp., Lexington, KY, USA) and read with a spectrophotometer at 450 nm. All Aβ, Tribody TM and conjugate dilutions were made in ELISA incubation buffer (PBS with 0.1% BSA, 0.05% Tween, and 0.15% Kathon). Aβ protein was purchased from American Peptide, Sunnyvale, CA, USA. Aβ monomers, protofibrils and fibrils were prepared as previously described (Magnusson et al., 2013; Sehlin et al., 2016) . All five bispecific proteins (A1-A5) were also assessed for TfR binding in comparison with 8D3. 96-well plates were coated over night at +4°C with 50 ng/well of recombinant TfR protein (Sinobiological, Beijing, China), then with 1% BSA in PBS for 1 h to lower the nonspecific binding. Serially diluted, biotinylated Tribody TM was incubated on the plate at room temperature for 2 h on a shaker and detected as above. All dilutions were made in ELISA incubation buffer.
Animals
Mice harbouring the Swedish (AβPP KM670/671NL) mutation (tgSwe) maintained on a C57BL/6 background display an onset of Aβ plaque pathology at 10-12 months of age with a subsequent rapid increase of pathology. Tg-ArcSwe mice, on a C57BL/6 background and harbouring both the Swedish and the Arctic mutation (AβPP E693G), are characterized by elevated levels of soluble Aβ protofibrils already at a very young age and dense core plaque pathology starting at 6 months of age (Lord et al., 2006; Philipson et al., 2009 ). In the present study, 
16-17 month old transgenic mice were used with wt littermates as control animals. For ex vivo studies, also young, 4-5 months, wt mice were used. The animals were housed with free access to food and water in rooms with controlled temperature and humidity in an animal facility at Uppsala University. All procedures described in this paper were approved by the Uppsala County Animal Ethics Board (#C17/14). All efforts were made to minimize animal suffering and to reduce the number of animals used.
Radiochemistry
The proteins studied ex vivo (A1, A2 and A3) and in vivo (A3) were labelled with iodine-125 ( 125 I) or iodine-124 ( 124 I) using direct radioiodination with the Chloramine-T method (Greenwood et al., 1963) . Table 2 . Blood samples (8 µl) were obtained from the tail vein at 0.5, 1, 2, 3, 4, 6, 24, 48 h after administration and mice were euthanized 2 h or 72 h after administration of the ligands.
At euthanization, mice were anaesthetized with isoflurane and a blood sample was obtained from the heart followed by intracardiac perfusion with 50 ml physiological saline during 2 min. The brain was then isolated and the cerebellum was separated from the rest of the brain. Liver, lung, kidney, heart, spleen, pancreas, muscle and the femoral bone were also isolated and radioactivity was measured in all samples with a γ-counter (1480 Wizard™, Wallac Oy, Turku, Finland).
The tissue and blood concentrations were quantified as % of injected dose per gram tissue (% ID/g).
PET imaging
PET imaging was performed with [ 124 I]A3 using a Triumph Trimodality System (TriFoil Imaging, Inc., Northridge, CA, USA). Animals were given water supplemented with 0.2% NaI on the day before radioligand administration to reduce thyroidal uptake of 124 I. Mice were i.v. injected with 12.6 ± 2.7 MBq [ 124 I]A3 with a specific activity of 136.4 ± 20.6 MBq/nmole. Half of the mice were PET/CT scanned at 1 and 3 days post injection while the other half were scanned at 2 and 3 days. PET scans obtained at 1 day post injection lasted for 30 min while scan time was 60 min on day 2 and 3. All PET scans were obtained in list mode and followed by a 3 min CT examination (Field of View (FOV)=8.0 cm). Mice were kept anesthetized with 1.5-2.0% isoflurane in 50% medical oxygen and 50% air during the PET and CT scans.
At day 3 animals were euthanized as above and radioactivity in blood, cerebrum (whole brain except cerebellum), cerebellum and isolated organs was measured with a well counter (GE Healthcare, Uppsala, Sweden).
PET data was reconstructed using the ordered subsets expectationmaximization (OSEM) 3D algorithm (20 iterations) and CT raw files were reconstructed using Filter Back Projection (FBP). All subsequent processing of the PET and CT images was performed in imaging software Amide 1.0.4 (Loening and Gambhir, 2003) . The CT scan was manually aligned with an MRI based mouse brain atlas (Ma et al., 2005) containing outlined regions of interests for hippocampus, striatum, thalamus, cerebral cortex, prefrontal cortex and cerebellum. The PET image was then aligned with the CT and MRI-atlas and PET data was quantified as a concentration ratio of the radioactivity in six regions of interest to that in cerebellum. In all PET experiments, mice were scanned in a randomized order.
Ex vivo autoradiography
Ex vivo autoradiography was performed on 20 µm thick sagittal brain sections of [ 124 I]A3 injected mice that previously had undergone PET scanning and 124 I standards of known radioactivity, placed in an X-ray cassette and exposed to positron-sensitive phosphor screens (MS, MultiSensitive, PerkinElmer, Downers grove, IL, USA). After 5 days, the plates were scanned at a resolution of 600 dots per inch in a Cyclone Plus Imager system (Perkin Elmer). The resulting digital images were converted to a false colour scale (Royal) with ImageJ and normalized to the standards.
Biochemical analysis of Aβ in brain tissue
Cerebrum (whole brain except cerebellum) and cerebellum concentrations of soluble and total Aβ were measured as previously (Sehlin et al., 2012 (Sehlin et al., , 2016 . In short, cerebrum or cerebellum tissue was homogenized at a 1:5 weight:volume ratio in TBS with complete protease inhibitors (Roche), then mixed 1:1 with TBS and centrifuged for 1 h at 16,000 g. For total Aβ, the original TBS extract was mixed with concentrated formic acid to a concentration of 70%, followed by homogenization and centrifugation as above. Aβ protofibrils were measured by coating a 96-well half-area plate overnight with 12.5 ng per well of 82E1 (IBL International/Tecan Trading AG, Switzerland), followed by blocking with 1% BSA in PBS. TBS extracts were diluted 1:25 (cerebrum) or 1:5 (cerebellum) and incubated overnight at +4°C, then detected with biotinylated 82E1 (0.25 µg/ml), SA-HRP (Mabtech AB) and K blue aqueous TMB substrate (Neogen Corp.). For Aβx-40 and Aβx-42, 96-well plates were coated overnight with 100 ng per well of polyclonal rabbit anti-Aβ40 or anti-Aβ42 (Agrisera, Umeå, Sweden), and blocked with 1% BSA in PBS. Formic acid extracts were neutralized with 2M Tris and diluted 100-10000 times depending on total Aβ concentration and incubated overnight at +4°C. After incubation with biotinylated 6E10 (0.5 µg/ml; Nordic BioSite, Täby, Sweden) signals Table 2 Number of mice, injected activity and specific activity in ex vivo and PET studies. were developed and read as above. All dilutions were made in ELISA incubation buffer.
Statistics
Results are presented as mean ± standard deviation. Data was analyzed with one-or two-way analysis of variance (ANOVA) followed by Bonferroni's or Dunnett's post hoc test. Pearson's correlation was used to analyze correlation of brain uptake of radioligands and Aβ protofibril concentrations. All analyses were performed in GraphPad Prism 6.0 (GraphPad Software, Inc, La Jolla, CA, USA). showed a stronger binding to Aβ protofibrils and the best selectivity over Aβ monomers ( Fig. 2A) . This suggests the longer linker length, with higher flexibility, increased the likelihood to obtain bivalent binding to Aβ protofibrils. Fibril binding was over-all 2-3 times lower than protofibril binding. All Tribodies TM were assessed for in vitro binding to TfR with the parent antibody 8D3 as control. A3, with a reversed order of the scFv-158 V H and V L , bound TfR with higher affinity than the other proteins, whereas 8D3, having two TfR binding sites, displayed a 10-fold stronger TfR binding, suggesting that it bound with higher avidity (Fig. 2B) . Based on these results, A1, A2 and A3, were chosen for further studies in wt and tg-Swe mice.
Results
3
Efficient transport across the BBB results in high radioligand concentrations in the brain
To study the in vivo BBB transport, young wt mice were administered with 125 I labelled Tribody TM and the brain, blood and organs were isolated 2 h later. The brain concentrations of all three ligands were remarkably high, around 1% ID/g which is 10-100 fold more than expected for antibodies and comparable to small molecular radioligands. At this early time point, there were no significant differences in distribution to any of the measured organs between A1, A2 and A3 (Fig. 3A) . The three ligands also displayed a similar cerebrum-to-blood concentration ratio, reflecting transport across the BBB (Fig. 3B) , and cerebrum-to-cerebellum ratio (Fig. 3C) . Next, old wt and tg-Swe mice were administered with the labelled proteins (A1-A3) and blood samples were obtained at various time points during 72 h. There was no difference in elimination of A1-A3 from blood between the wt and tg-Swe mice. The half-life in blood calculated from 1 h to 72 h was (mean ± s.d.) 9.0 ± 0.3 h, 8.5 ± 0.6 h and 9.0 ± 0.5 h for A1, A2 and A3, respectively. Biodistribution to different organs did not differ between the three different proteins (Fig. 4A-C) , whereas the cerebrum concentration and the cerebrum-tocerebellum concentration ratio, reflecting specific binding in the brain, seemed most favorable for A3 (Fig. 4D) . A3 also displayed the highest brain retention in relation to the post mortem measured brain levels of Aβ protofibrils (Fig. 4E) . Summarizing the in vitro and ex vivo results, A3 appeared to be the best performing Tribody I and administered to 8 wt, 9 tg-Swe and 4 tg-ArcSwe mice. One day post injection, radioactivity in the periphery gave rise to a higher PET signal than the signal obtained in the brain region in both transgenic and wt mice. (Fig. 5A) . At two and three days, radioactivity was gradually eliminated from blood and tissue surrounding the brain, and the difference between transgenic and wt mice became evident, as the radioligand was retained in the transgenic mouse brain, bound to Aβ. At three days, both tg-Swe and tg-ArcSwe mice showed substantial retention of the ligand in the brain, especially in cortical regions, known to contain large amounts of Aβ at this age, and the distinction between Aβ containing and unaffected regions (i.e. the cerebellum) was clearly visible. At this time, wt brains were devoid of radioactivity, as non-bound ligand had been washed out of the brain. Deiodination of [ 124 I]A3 was less than 10% in the injection solution and 13 ± 12% in terminal plasma.
Ex vivo autoradiography was performed on perfused brains from PET scanned animals to assess the brain distribution of [ 124 I]A3 without interference from ligand in the blood (Fig. 5B ). This analysis confirmed that the radioligand accumulated primarily in the prefrontal brain areas in both transgenic models, whereas wt brains were nearly blank in all regions.
PET data was quantified as the ratio between the radioactivity in the regions of interest to that in the cerebellum (Fig. 5C-E) . This ratio was around 1 in all regions at all time points in wt mice, whereas it increased over time in tg-Swe and tg-ArcSwe mice, with highest values in prefrontal cortex, followed by hippocampus. There were significant differences in [
124 I]A3 accumulation between transgenes and wt mice in some regions (e.g. cortex and striatum) already at 1 day post injection. At day 3, all studied regions displayed higher ratios in transgenic mice.
PET quantification of [ 124 I]A3 brain concentration correlates with Aβ pathology
The Aβ pathology of PET scanned mouse brains was assessed with ELISAs measuring soluble Aβ protofibrils, i.e. the main target of the ligand, as well as formic acid soluble total Aβ40 and Aβ42, which is a good measure of the total burden of amyloid plaques (Magnusson et al., 2013) (Fig. 6B) , whereas total Aβ42 did not (Fig. 6C ). This may be explained by A3's intermediate binding also to Aβ fibrils, abundantly present in the amyloid plaques, mainly consisting of Aβ40 in these mouse models.
The cerebrum to cerebellum ratio of Aβ protofibrils, based on ELISA measured concentrations, correlated closely with the concentration of protofibrils in cerebrum (due to the constant low Aβ levels in cerebellum), and was used for comparison with PET data (Fig. 6D) . A good correlation was seen between the Aβ protofibril ratio and the cerebrum/cerebellum PET ratio (Fig. 6E ) and an even stronger correlation was observed for the brain region with the most pronounced [ 124 I]A3 brain retention, i.e. prefrontal cortex (Fig. 6F) .
Discussion
The present study describes, to our knowledge for the first time, a radioligand that was recombinantly produced as a bispecific protein and successfully used for molecular imaging within the CNS. PET radioligands intended for imaging of intra-brain targets have so far been based on small drug-like compounds. Development of such ligands is often hampered by considerable non-specific binding due to their fairly lipophilic nature, required for sufficient distribution into the brain. Antibodies and engineered forms and fragments of them usually display highly specific binding with low background signal. Further, and especially relevant in proteopathies such as AD, it is unlikely that small molecular radioligands could distinguish between different aggregation forms of a single protein. The ability of antibodies to do so was utilized in the present study in which Aβ pathology and particularly soluble Aβ protofibrils were imaged. Thus, in line with the therapeutic focus shift from small molecular drugs to biologics, we believe that the use of antibodies or fragments thereof can be used for CNS PET imaging, leading to highly specific imaging agents.
Macromolecules such as antibodies do not efficiently enter the brain. Hence, in the present study the Fab moiety of the Tribody TM was based on a well-studied TfR antibody, 8D3, to enable TfR mediated transcytosis into the brain. Although the Fab was the same in all five versions (A1-A5), A3 displayed a greater TfR affinity compared with the other versions. This was not reflected by in vivo concentration of the ligands determined in brain tissue isolated 2 h post injection (Fig. 3B) . However, three days after administration, there was a tendency that A3 displayed the highest brain concentrations in relation to brain levels of Aβ protofibrils (Fig. 3E) as well as the largest difference between tg-Swe and wt mice (16-fold). Based on the ex vivo findings and the higher in vitro affinity to TfR, we decided to continue with A3, as a higher TfR affinity has been reported to increase brain uptake at trace doses (Yu et al., 2011 ]A3 was visible in cortex in tg-ArcSwe and tg-Swe mice. At three days, the new radioligand visualized brain regions known to contain large amounts of Aβ pathology, while cerebellum displayed low levels of radioactivity in both models. In wt mice, which completely lack the intra-brain target for [ 124 I]A3, the ligand was washed out from the brain and almost no activity was detected in any brain region (Fig. 5A) . These results were visually confirmed with ex vivo autoradiography, were the blood was removed from the brain tissue, leaving only bound radioligand to be detected in transgenic mouse brain sections, while wt sections were blank. Quantification of the PET data, as a concentration ratio between the region of interest and cerebellum, showed that transgenic mice displayed a significantly elevated ratio already one day post injection in regions containing large amount of Aβ pathology, and the difference to wt mice increased with time ( Fig. 5C-E) . Previous studies using small molecular Aβ PET ligands have reported maximum in vivo cortex-tocerebellum ratios of 1.3-1.4 in transgenic mouse models characterized by large amounts of dense core plaques (Brendel et al., 2015; Sehlin et al., 2016; Snellman et al., 2013) , while mice harboring only the Swedish mutation and thus loose structured plaques have displayed ratios just above or close to 1, i.e. almost the same ratio as seen in wt mice (Brendel et al., 2015; Kuntner et al., 2009; Snellman et al., 2013) . Both tg-ArcSwe and tg-Swe mice studied with [ 124 I]A3 displayed cortex-to-cerebellum ratios of 2.5, while wt mice displayed the expected ratios of 1. Thus, [
124 I]A3 was superior compared with small molecular Aβ radioligands for differentiation between transgenic and wt mice, and in addition, binding was not dependent on dense core plaque pathology. For an extensive review of ex vivo measured Aβ and the impact on brain retention of [ 11 C]PIB and analogues in transgenic mouse models, the reader is referred to Brendel et al. 2015 . At three days there was a discrepancy between the cerebrum-tocerebellum ratio measured ex vivo and with PET. This was mainly attributed to the radioactivity in the cerebellar blood volume, overestimating the ligand concentration in the reference region, which leads to an underestimation of the cerebrum-to-cerebellum ratio. However, the use of cerebellum as a reference region was supported (Sehlin et al., 2016) , but PET images obtained with the two ligands were qualitatively similar. The PET images obtained with these two antibody ligands were also comparable to images obtained with small molecular radioligands that in general display 10-fold higher brain concentrations at the time of PET scanning. This shows the benefit of low non-specific binding exhibited by antibody based ligands and strengthens the notion that the image quality cannot be predicted based on the concentration of the (free) ligand in brain but rather the ratio of specific to non-specific signal.
The difficulties with antibody based radioligands is therefore not the extent of brain delivery per se but rather the slow elimination from blood. The half-life in blood of the proteins was about 9 h and can be compared to the 270 kDa fusion protein 8D3-F(ab') 2 -h158 with a 15 h half-life. The Tribody TM is fairly small in comparison (100 kDa) and does not contain an Fc domain, which is associated with a long systemic half-life for antibodies (usually weeks) and may explain why A3 exhibited a faster wash-out from the wt brain, compared with 8D3-F(ab') 2 -h158. This in turn probably explains why A3 displayed a larger difference in brain retention between transgenic and wt mice 3 days post injection (16-fold difference for A3 compared with 7-fold difference for 8D3-F(ab') 2 -h158). ]A3 relative to that in cerebellum at C) 1 day, D) 2 days and E) 3 days after administration. In tg-Swe and tg-ArcSwe mice this ratio increased with time while it remained stable around 1 in wt mice regardless of region and scanning occasion. At 3 days, the ratio was significantly increased in all studied regions in tgSwe and tg-ArcSwe mice compared with wt mice (Two-way ANOVA with Dunnett's multiple comparisons test, * p < 0.05, ** p < 0.01, *** p < 0.001).
PET imaging has made an important contribution to AD diagnosis and research over the past decade, since the introduction of the amyloid ligand [
11 C]PIB (Klunk et al., 2004) . However, [ 11 C]PIB and its analogues all bind to insoluble, fibrillar Aβ in the dense amyloid plaques and thus give a rather static picture of the Aβ pathology, reaching a ceiling early in the disease process. By targeting soluble Aβ protofibrils, a pre-stage of fibrils, we hope to obtain a more dynamic image of the different stages of pathology and also to be able to measure effects of Aβ lowering treatment. We previously described that antibody-based PET imaging can dynamically depict Aβ pathology in transgenic mice of different ages and the present study, with a recombinantly expressed Tribody TM , is an improvement of this method and a step further towards clinical PET imaging of Aβ protofibrils. Further, A3 or similar antibody-based ligands labelled with long-lived radionuclide 125 I could in theory also be used for longitudinal monitoring of Aβ lowering treatments with SPECT.
In conclusion, this study describes the reengineering of our Aβ protofibril selective antibody mAb158 into a Tribody TM format, with two scFv-158 and a Fab fragment of the TfR binding antibody 8D3. We thus obtained a recombinant, antibody-based ligand, which is actively transcytosed into the brain, to target Aβ protofibrils. With the radiolabeled protein, [
124 I]A3, we could selectively visualize Aβ pathology in vivo with PET. This method holds promise for dynamic imaging of Aβ pathology in AD patients and could easily be adopted to imaging a variety of disease causing proteins in the brain.
